insights_auto
Why is 688235 up 4,06%?
Dive Deeperchevron_right
688235:SHA
BeOne Medicines AG
CN¥255,98
arrow_upward
+4,06%(+9,99) 1D
16 Okt., 15:00:00 GMT+8 · CNY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 688235...
Open
CN¥253,20
High
CN¥268,18
Low
CN¥252,09
Mkt. cap
289,03 mjd
Avg. vol.
2,81 m
Volume
5,69 m
P/E ratio
91,43
52-wk high
CN¥319,24
52-wk low
CN¥205,51
EPS
CN¥2,80
No. of employees
12 k
Open
CN¥253,20
High
CN¥268,18
Low
CN¥252,09
Mkt. cap
289,03 mjd
Avg. vol.
2,81 m
Volume
5,69 m
P/E ratio
91,43
52-wk high
CN¥319,24
52-wk low
CN¥205,51
EPS
CN¥2,80
No. of employees
12 k
News stories
From web sources and news partners
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12 k
Founded28 Okt. 2010
Headquarters-
Sector-
Websitebeonemedicines.com